BACKGROUND: Cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) show an acceptable diagnostic sensitivity and specificity; however, their interpretation and ease of use is far from optimal. OBJECTIVE: To study and validate the diagnostic accuracy of an easy-to-use normalized CSF biomarker index, the AD-CSF-index, in different European populations. METHODS: A total of 342 subjects, 103 healthy controls and 239 AD patients, from four European memory clinics were included. The AD-CSF-index was constructed from the addition of normalized values between the minimum and maximum of amyloid and tau protein levels. The diagnostic accuracy, receiver operating characteristic, and regression analysis of the AD-CSF-index and other composite indices were evaluated in this study. RESULTS: AD patients presented a significantly higher AD-CSF-index than healthy subjects (control = 0.5204; AD = 1.2272; p < 0.001). The AD-CSF-index obtained a sensitivity of 88.6% at 85% specificity and also showed a significantly higher diagnostic power (p < 0.05) than the individual CSF biomarkers and other studied indices. The performance of the AD-CSF-index was very similar between ELISA and MesoScale measurements. Cut-off values of approximately 0.75 provided the lowest achievable overall classification errors and a cut-off point of about 0.95 consistently provided specificities above 85%. CONCLUSION: The AD-CSF-index represents a novel approach, combining normalized CSF values, for the biological diagnosis of AD. The AD-CSF-index presents an optimal AUC with high sensitivity and specificity and seems to be a simple and intuitive way to interpret AD CSF biomarker results even from different analytical platforms.
BACKGROUND: Cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) show an acceptable diagnostic sensitivity and specificity; however, their interpretation and ease of use is far from optimal. OBJECTIVE: To study and validate the diagnostic accuracy of an easy-to-use normalized CSF biomarker index, the AD-CSF-index, in different European populations. METHODS: A total of 342 subjects, 103 healthy controls and 239 AD patients, from four European memory clinics were included. The AD-CSF-index was constructed from the addition of normalized values between the minimum and maximum of amyloid and tau protein levels. The diagnostic accuracy, receiver operating characteristic, and regression analysis of the AD-CSF-index and other composite indices were evaluated in this study. RESULTS: AD patients presented a significantly higher AD-CSF-index than healthy subjects (control = 0.5204; AD = 1.2272; p < 0.001). The AD-CSF-index obtained a sensitivity of 88.6% at 85% specificity and also showed a significantly higher diagnostic power (p < 0.05) than the individual CSF biomarkers and other studied indices. The performance of the AD-CSF-index was very similar between ELISA and MesoScale measurements. Cut-off values of approximately 0.75 provided the lowest achievable overall classification errors and a cut-off point of about 0.95 consistently provided specificities above 85%. CONCLUSION: The AD-CSF-index represents a novel approach, combining normalized CSF values, for the biological diagnosis of AD. The AD-CSF-index presents an optimal AUC with high sensitivity and specificity and seems to be a simple and intuitive way to interpret AD CSF biomarker results even from different analytical platforms.
Authors: Sérgio M de Almeida; Clea E Ribeiro; Indianara Rotta; Scott Letendre; Michael Potter; Bin Tang; Meiri Batistela; Florin Vaida; Ronald J Ellis Journal: J Neurovirol Date: 2019-07-07 Impact factor: 2.643
Authors: Sérgio Monteiro de Almeida; Clea E Ribeiro; Indianara Rotta; Mauro Piovesan; Bin Tang; Florin Vaida; Sonia Mara Raboni; Scott Letendre; Michael Potter; Meire S Batistela Fernandes; Ronald J Ellis Journal: J Neurovirol Date: 2017-10-23 Impact factor: 2.643
Authors: Alberto Lleó; Enrica Cavedo; Lucilla Parnetti; Hugo Vanderstichele; Sanna Kaisa Herukka; Niels Andreasen; Roberta Ghidoni; Piotr Lewczuk; Andreas Jeromin; Bengt Winblad; Magda Tsolaki; Barbara Mroczko; Pieter Jelle Visser; Isabel Santana; Per Svenningsson; Kaj Blennow; Dag Aarsland; José Luis Molinuevo; Henrik Zetterberg; Brit Mollenhauer Journal: Nat Rev Neurol Date: 2014-12-16 Impact factor: 42.937
Authors: Daniel Ferreira; Lilisbeth Perestelo-Pérez; Eric Westman; Lars-Olof Wahlund; Antonio Sarría; Pedro Serrano-Aguilar Journal: Front Aging Neurosci Date: 2014-03-24 Impact factor: 5.750
Authors: Juan Domingo Gispert; Gemma C Monté; Marc Suárez-Calvet; Carles Falcon; Alan Tucholka; Santiago Rojas; Lorena Rami; Raquel Sánchez-Valle; Albert Lladó; Gernot Kleinberger; Christian Haass; José Luis Molinuevo Journal: Alzheimers Dement (Amst) Date: 2016-12-22
Authors: Murat Demirtaş; Carles Falcon; Alan Tucholka; Juan Domingo Gispert; José Luis Molinuevo; Gustavo Deco Journal: Neuroimage Clin Date: 2017-08-08 Impact factor: 4.881